Sign In
Buy CRL
$179.87
+5.08 (+2.91%)
At Close: Jun 03, 2026
Deciphering Charles River (CRL) International Revenue Trends
10:15am, Monday, 24'th Feb 2025
Examine the evolution of Charles River's (CRL) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects.
Analyst Sees Charles River As Preclinical Leader But Maintains Neutral Stance
04:58pm, Wednesday, 19'th Feb 2025
On Wednesday, Charles River Laboratories International Inc CRL reported fourth-quarter 2024 revenue of $1 billion, a decrease of 1.1% year over year, beating the consensus of $983.63 million.
Charles River Laboratories International, Inc. (CRL) Q4 2024 Earnings Call Transcript
03:03pm, Wednesday, 19'th Feb 2025
Charles River Laboratories International, Inc. (NYSE:CRL ) Q4 2024 Earnings Call February 19, 2025 8:30 AM ET Company Participants Todd Spencer - Vice President, Investor Relations Jim Foster - Chair,
CRL Stock Up on Q4 Earnings and Revenue Beat, Margins Fall
02:55pm, Wednesday, 19'th Feb 2025
Charles River's organic revenue growth in Manufacturing Solutions is more than offset by lower revenues in the RMS and DSA segments.
Compared to Estimates, Charles River (CRL) Q4 Earnings: A Look at Key Metrics
10:35am, Wednesday, 19'th Feb 2025
The headline numbers for Charles River (CRL) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street
Charles River Laboratories (CRL) Tops Q4 Earnings and Revenue Estimates
09:10am, Wednesday, 19'th Feb 2025
Charles River Laboratories (CRL) came out with quarterly earnings of $2.66 per share, beating the Zacks Consensus Estimate of $2.50 per share. This compares to earnings of $2.46 per share a year ago.
Charles River beats quarterly estimates on stable demand for drug development services
08:11am, Wednesday, 19'th Feb 2025
Charles River Laboratories on Wednesday beat fourth-quarter profit and revenue estimates, helped by stable demand for its drug discovery and development services from biotech clients.
Gear Up for Charles River (CRL) Q4 Earnings: Wall Street Estimates for Key Metrics
10:21am, Monday, 17'th Feb 2025
Get a deeper insight into the potential performance of Charles River (CRL) for the quarter ended December 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates
Is Now the Right Time to Hold on to Charles River Stock?
06:51am, Friday, 14'th Feb 2025
CRL's solid prospects in the DSA segment and strategic partnerships present a promising opportunity for investors.
Charles River Laboratories (CRL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
11:06am, Wednesday, 12'th Feb 2025
Charles River (CRL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Charles River and Deciphex Extend Global Partnership to Expand Digital Pathology Offering with Exclusive Image Management Solutions
08:00am, Tuesday, 11'th Feb 2025
WILMINGTON, Mass. & DUBLIN--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River and Deciphex focus on advancing image management solutions, while developing novel AI tools for toxicologic pathology.
CRL Gears Up for Q4 Earnings: Here's What You Need to Know
08:45am, Monday, 03'rd Feb 2025
Growth across the Manufacturing and RMS segments is likely to have contributed to Charles River's fourth-quarter revenues.
Charles River Launches Apollo for CRADL to Boost Research, Stock Rises
09:21am, Wednesday, 22'nd Jan 2025
CRL introduces Apollo for CRADL, integrating the technology stack across its robust portfolio.
Charles River Expands Apollo™ Ecosystem, Offering Bespoke Client Experiences
08:00am, Tuesday, 21'st Jan 2025
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River expands Apollo ecosystem, offering bespoke client experiences that enable data-driven decision making.
Atara Biotherapeutics: Another Dip Buying Opportunity Following CRL For CMC Issues
12:21am, Tuesday, 21'st Jan 2025
Atara has just announced a CRL by FDA for EBVALLO. EBVALLO is already approved in Europe since December 2022 and the cause of the CRL seems minor and easily addressable. The CRL has a major impact on
